SEATTLE — The PULSAR trial in wet age-related macular degeneration demonstrated that aflibercept 8 mg administered every 12 or 16 weeks is noninferior in vision gains compared with aflibercept 2 mg every 8 weeks.
The 48-week outcomes of the trial were presented at the American Society of Retina Specialists annual meeting by Jignesh Patel, MD, FRCOphth.
“The primary endpoint was the change in best corrected visual acuity from baseline to week 48 with a noninferiority margin of four letters. The key secondary endpoint was the proportion of patients who were (Read more...)